静脉滴注加雾化吸入沐舒坦在新生儿肺炎治疗中的疗效分析

Effect analysis of intravenous infusion and atomization inhalation of mucosolvan in the treatment of neonatal pneumonia

目的 探讨静脉滴注加雾化吸入沐舒坦治疗新生儿肺炎的临床效果.方法 选取2016年3月至2017年3月我院收治的62例肺炎患儿作为研究对象,根据治疗方法分为观察组和对照组,各31例.对照组采用静脉滴注沐舒坦进行治疗,观察组则采用静脉滴注加雾化吸入沐舒坦进行治疗.比较两组患儿的治疗总有效率、住院时间、咳嗽消失时间、肺音消失时间、呼吸急促消失时间以及不良反应发生率.结果 观察组患儿的治疗总有效率（93.55%）明显高于对照组（67.74%）,差异具有统计学意义（P＜0.05）;观察组的不良反应率（3.23%）明显低于对照组（22.58%）,差异具有统计学意义（P＜0.05）;观察组的住院时间、咳嗽消失时间、肺音消失时间、呼吸急促消失时间均短于对照组,差异均具有统计学意义（P＜0.05）.结论 静脉滴注加雾化吸入沐舒坦治疗新生儿肺炎,可以有效地促进患儿恢复,减少不良反应,值得临床推广.

Objective To explore the efficacy of intravenous infusion and atomization inhalation of mucosolvan in the treatment of neonatal pneumonia. Methods From March 2016 to March 2017, 62 cases of children with pneumonia treated in our hospital were selected as research objects, and divided into observation group and control group according to treatment methods, with 31 cases in each group. The control group was treated with intravenous infusion of mucosolvan, while the ob- servation group was treated with intravenous infusion and atomization inhalation of mucosolvan. The total effective rate, hos- pitalization time, cough disappearance time, pulmonary rales disappearance time, shortness of breath disappearance time and the incidence of adverse reactions of the two groups were compared. Results The total effective rate of the observation group （93.55%） was significant higher than that of the control group （67.74%）, the difference was statistically significant （P〈0.05）; The adverse response rate （3.23%） of the observation group was significantly lower than that of the control group （22.58%）, the difference was statistically significant （P〈0.05）; the hospitalization time, disappearance time of cough, pulmonary tales disappearance time and shortness of breath disappearance time of the observation group were lower than those of the control group, the differences were statistically significant （P〈0.05）. Conclusion The treatment of intravenous infusion and atomiza- tion inhalation of mucosolvan can effectively promote the recovery of children with pneumonia and reduce adverse reactions, it is worthy of clinical promotion.